Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market >>>>

Roots Analysis has done a detailed study on “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020- 2030”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this link
Key Market Insights 
  • Close to 120 companies across the globe claim to possess the required expertise and infrastructure to offer contract manufacturing services for HPAPIs and cytotoxic drugs
  • The market is fragmented, featuring the presence of both established players and new entrants based in different geographies that claim to be capable of manufacturing highly potent products, at varying scales of operation
  • In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies offering services across different scales of operation have established presence in various geographical regions
  • In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been inked related to highly potent drug products
  • In order to enhance the core competencies in this domain, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities
  • Most of the installed, global HPAPI and cytotoxic drug manufacturing capacity belongs to established CMOs, accounting for close to 75% of the available capacity across various geographies
  • Case-in-point: ADCs represent a significant growth opportunity; over 30 CMOs currently extend their services to manufacture one or multiple components of an ADC molecule
  • We expect highly potent drug developers to continue to outsource their manufacturing operations in the mid to long term, causing service-based revenues to grow at an annualized rate of more than 10%
In the long-term, the projected opportunity for the contract manufacturing of HPAPIs and cytotoxic drugs is likely to be well distributed across various dosage forms, nature of molecules and sizes of contract service providers
For more information, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  
 
Table of Contents
 
1.         PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Highly Potent Active Pharmaceutical Ingredients (HPAPIs)
3.2.1. Classification based on Potency of Pharmacological Ingredients
3.2.2. Types of HPAPIs
3.2.3. Challenges Associated with Handling HPAPIs
3.2.4. Considerations for Handling HPAPIs
3.2.5. Contract Manufacturing of HPAPIs and Cytotoxic Drugs
3.2.5.1. Selection of a Suitable CMO Partner for HPAPI Manufacturing
3.2.6. Regulatory Considerations for HPAPI Manufacturing
3.2.7.    Concluding Remarks
4.         MARKET LANDSCAPE
4.1. Chapter Overview
4.2. HPAPI and Cytotoxic Drugs Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Type of Service(s) Offered
4.2.5. Analysis by Type of Product
4.2.6. Analysis by Type of Pharmacological Molecule
4.2.7. Analysis by Location of Headquarters
4.2.8. Analysis by Location of Manufacturing Facilities
4.2.9. Analysis by Facility Size
4.2.10. Analysis by Type of Highly Potent Finished Dosage Forms (FDFs)
4.2.11. Analysis by Type of Primary Packaging
5.         COMPANY COMPETITIVE ANALYSIS
5.1.       Chapter Overview
5.2.       Methodology
5.3.       Assumptions and Key Parameters
5.4.       Company Competitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturers based     in North America
5.5.       Company Competitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe
5.6.       Company Competitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific and Rest of the World
            
6.         HPAPI AND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN NORTH AMERICA: COMPANY PROFILES
6.1.       Chapter Overview
6.2.       AbbVie Contract Manufacturing
6.2.1.    Company Overview
6.2.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
6.2.1.2. Manufacturing Facilities
6.2.1.3. Recent Developments
6.2.1.4. Future Outlook
 
6.3.       Catalent
6.3.1.    Company Overview
6.3.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
6.3.1.2. Manufacturing Facilities
6.3.1.3. Recent Developments
6.3.1.4. Future Outlook
 
6.4.       Pfizer CentreOne
6.4.1.    Company Overview
6.4.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
6.4.1.2. Manufacturing Facilities
6.4.1.3. Recent Developments
6.4.1.4. Future Outlook
 
6.5.       Piramal Pharma Solutions
6.5.1.    Company Overview
6.5.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
6.5.1.2. Manufacturing Facilities
6.5.1.3. Recent Developments
6.5.1.4. Future Outlook
 
6.6.       SAFC (a business division of Sigma-Aldrich)
6.6.1.    Company Overview
6.6.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
6.6.1.2. Manufacturing Facilities
6.6.1.3. Recent Developments
6.6.1.4. Future Outlook
 
7.         HPAPI AND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN EUROPE: COMPANY PROFILES
7.1.       Chapter Overview
7.2.       Carbogen Amics
7.2.1.    Company Overview
7.2.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
7.2.1.2. Manufacturing Facilities
7.2.1.3. Recent Developments
7.2.1.4. Future Outlook
 
7.3.       Evonik
7.3.1.    Company Overview
7.3.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
7.3.1.2. Manufacturing Facilities
7.3.1.3. Recent Developments
7.3.1.4. Future Outlook
 
7.4.       Lonza
7.4.1.    Company Overview
7.4.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
7.4.1.2. Manufacturing Facilities
7.4.1.3. Recent Developments
7.4.1.4. Future Outlook
 
7.5.       Siegfried
7.5.1.    Company Overview
7.5.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
7.5.1.2. Manufacturing Facilities
7.5.1.3. Recent Developments
7.5.1.4. Future Outlook
 
7.6.       Teva API
7.6.1.    Company Overview
7.6.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
7.6.1.2. Manufacturing Facilities
7.6.1.3. Recent Developments
7.6.1.4. Future Outlook


8.         HPAPI AND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN ASIA PACIFIC: COMPANY PROFILES
8.1.       Chapter Overview
8.2.       Formosa Laboratories
8.2.1.    Company Overview
8.2.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
8.2.1.2. Manufacturing Facilities
8.2.1.3. Recent Developments
8.2.1.4. Future Outlook
 
8.3.       Intas Pharmaceuticals
8.3.1.    Company Overview
8.3.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
8.3.1.2. Manufacturing Facilities
8.3.1.3. Future Outlook
 
8.4.       MabPlex
8.4.1.    Company Overview
8.4.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
8.4.1.2. Manufacturing Facilities
8.4.1.3. Future Outlook
 
8.5.       ScinoPharm
8.5.1.    Company Overview
8.5.1.1. HPAPIs and Cytotoxic Drugs Manufacturing Service Offerings
8.5.1.2. Manufacturing Facilities
8.5.1.3. Future Outlook
 
8.6.       STA Pharmaceutical (a WuXi AppTec company)
8.6.1.    Company Overview
8.6.1.1. HPAPI and Cytotoxic Drugs Manufacturing Service Offerings
8.6.1.2. Manufacturing Facilities
8.6.1.3. Recent Developments
8.6.1.4. Future Outlook


9.         PARTNERSHIPS AND COLLABORATIONS
9.1.       Chapter Overview
9.2.       Partnership Models
9.3.       HPAPI and Cytotoxic Drugs Contract Manufacturers: List of Partnerships and Collaborations
9.3.1.    Analysis by Year of Partnership
9.3.2.    Analysis by Type of Partnership
9.3.3.    Analysis by Type of Product
9.3.4.    Analysis by Scale of Operation
9.3.5.    Analysis by Company Size
9.3.6.    Analysis of Acquisitions by Amount Invested
9.3.7.    Most Active Players: Analysis by Number of Partnerships
9.3.8.    Geographical Analysis
9.3.8.1. Continent-wise Distribution
9.3.8.2. Country-wise Distribution


10.        RECENT EXPANSIONS
10.1.     Chapter Overview
10.2.     HPAPI and Cytotoxic Drugs Contract Manufacturers: Recent Expansions
10.2.1.  Analysis by Year of Expansion
10.2.2.  Analysis by Type of Expansion
10.2.3.  Analysis by Scale of Operation and Type of Expansion
10.2.4.  Analysis by Type of Product and Type of Expansion
10.2.5.  Analysis by Expanded Facility Area 
10.2.6.  Analysis by Amount Invested
10.2.7.  Analysis by Company Headquarters and Company Size
10.2.8.  Analysis by Location of Facility and Type of Expansion
10.2.9.  Most Active Players: Analysis by Number of Expansions
10.2.10. Geographical Analysis 
10.2.10.1. Continent-wise Distribution
10.2.10.2. Country-wise Distribution


11.        CAPACITY ANALYSIS
11.1.     Chapter Overview
11.2.     Key Assumptions and Methodology
11.3.     HPAPI and Cytotoxic Drugs Contract Manufacturers: Global, Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Manufacturing Facility
11.4.     Concluding Remarks


12.        MAKE VERSUS BUY DECISION MAKING FRAMEWORK
12.1.     Chapter Overview
12.2.     HPAPI and Cytotoxic Drugs Contract Manufacturing: Make versus Buy Decision Making
 
13.        MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1.     Chapter Overview
13.2.     Forecast Methodology and Key Assumptions
13.3.     Overall HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030 
13.4.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030:  Distribution by Type of Product
13.5.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Company Size
13.6.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.7.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Pharmacological Molecule
13.8.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Highly Potent Finished Dosage Forms
13.9.     HPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution across Key Geographical Regions
13.9.1.  HPAPI and Cytotoxic Drugs Contract Manufacturing Market in North America, 2020-2030
13.9.1.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the US, 2020-2030
13.9.1.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Canada, 2020-2030
13.9.1.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Mexico, 2020-2030
13.9.2.  HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Europe, 2020-2030
13.9.2.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the UK, 2020-2030
13.9.2.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Italy, 2020-2030
13.9.2.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Germany, 2020-2030
13.9.2.4. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in France, 2020-2030
13.8.2.5. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Spain, 2020-2030
13.9.2.6. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030
13.9.3.    HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Asia Pacific, 2020-2030 (USD Billion)
13.9.3.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in China, 2020-2030
13.9.3.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in India, 2020-2030
13.9.3.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Rest of Asia Pacific, 2020-2030
13.9.4.  HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the Rest of the World, 2020-2030


14.        SWOT ANALYSIS
14.1.     Chapter Overview
14.2.     Strengths
14.3.     Weaknesses
14.4.     Opportunities
14.5.     Threats
14.6.     Concluding Remarks
 
15.        CASE-IN-POINT: CONTRACT MANUFACTURING OF ANTIBODY DRUG CONJUGATES
15.1.     Chapter Overview
15.2.     Key Components of ADCs
15.2.1.  Antibody
15.2.2.  Cytotoxin
15.2.3.  Linker
15.3.     Overview of ADC Manufacturing 
15.3.1.  Key Process Steps 
15.3.2.  Challenges Associated with ADC Manufacturing 
15.3.3.  Growing Trend of Outsourcing in ADC Manufacturing
15.4.     Challenges Associated with Supply Chain and Method Transfer
15.5.     Growing Demand for One-Stop-Shops and Integrated Service Providers
15.6.     Key Considerations for Selecting a CMO Partner
15.7.     ADC Contract Manufacturers: Overall Market Landscape
15.7.1.  Analysis by Location of Headquarters
15.7.2.  Analysis by Year of Establishment
15.7.3.  Analysis by Company Size
15.7.4.  Analysis by Service(s) Offered
15.7.5.  Analysis by Location of Headquarters 
15.7.5.  Analysis by Location of Manufacturing Facility
15.7.6.  Analysis by Scale of Operation
 
16.        CONCLUDING REMARKS

 

17.        EXECUTIVE INSIGHTS
17.1.     Chapter Overview
 
17.2.     BSP Pharmaceuticals 
17.2.1.  Company Snapshot
17.2.2.  Interview Transcript: Antonella Mancuso and Maria Elena Guadagno, Vice President and Chief Operating Officer and Business Director
 
17.3.     Catalent
17.3.1.  Company Snapshot 
17.3.2.  Interview Transcript: Stacy McDonald and Jennifer L. Mitcham, Group Product Manager and Director-Business Development
 
17.4.     CordenPharma 
17.4.1.  Company Snapshot 
17.4.2.  Interview Transcript: Roberto Margarita, Business Development Director
 
17.5.     Helsinn
17.5.1.  Company Snapshot 
17.5.2.  Interview Transcript: Allison Vavala, Senior Manager, Business Development 
 
17.6.     Idifarma 
17.6.1.  Company Snapshot 
17.6.2.  Interview Transcript: Javier E. Aznárez Araiz, Business Development
 
17.7.     Piramal Healthcare 
17.7.1.  Company Snapshot 
17.7.2.  Interview Transcript: Dr. Mark Wright, Site Head, Grangemouth
 
17.8      ProJect Pharmaceutics 
17.8.1.  Company Snapshot 
17.8.2.  Interview Transcript: Klaus Hellerbrand, Managing Director
 
17.9.     Alphora Research 
17.9.1.  Company Snapshot 
17.9.2.  Interview Transcript: Kevin Rosenthal, Business Head, Formulations and Finished Products


18.        APPENDIX 1: TABULATED DATA

 

19.        APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS


Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
747 Posts

Made with by Mamby